English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The aim of the study was to evaluate the possible association between plasma concentrations of transforming growth factor-β 1  (TGF-β 1 ) and the degree of hepatic dysfunction in patients with chronic liver diseases. TGF-β 1  was measured with an enzyme immunoassay in plasma from 21 patients with chronic active hepatitis and 40 patients with liver cirrhosis. Normal values were obtained from a group of 13 healthy volunteers. Results were analysed with respect to aetiology and the degree of liver insufficiency as evaluated by the Child-Pugh classification. The mean plasma concentration of TGF-β 1 in patients 36.9±2.8 ng/ml) was twice that found in normal volunteers (18.3±1.6 ng/ml). The highest values were observed in patients with alcoholic liver cirrhosis (44.4±4.7 ng/ml). Plasma TGF-β 1  showed a statistically significant positive correlation with the degree of liver insufficiency. These results indicate the possible use of plasma TGF-β 1  measurement as a good marker of liver function impairment. Further observation of patients involved in this study may help to evaluate its possible prognostic value in chronic liver diseases.

Transforming Growth Factor-β1 as a Surrogate Marker of Hepatic Dysfunction in Chronic Liver Diseases